483987-67-3Relevant academic research and scientific papers
Heterocycles useful in the treatment of benign prostatic hyperplasia
-
Page column 25, (2010/02/05)
This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the α-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.
Arylpiperazine substituted heterocycles as selective alpha(1a) adrenergic antagonists.
Khatuya, Haripada,Hutchings, Richard H,Kuo, Gee-Hong,Pulito, Virginia L,Jolliffe, Linda K,Li, Xiaobing,Murray, William V
, p. 2443 - 2446 (2007/10/03)
Antagonists of the alpha(1)-adrenergic receptors (alpha(1)-ARs) are useful for the treatment of benign prostatic hyperplasia. A series of potent and subtype-selective alpha(1a)-AR antagonists has been synthesized, displaying in vitro binding affinity in the low the nanomolar range.
